Trastuzumab News and Research

RSS

Immune system B-cells may be better in predicting HER2-positive breast cancer treatment response

Researchers at UNC Lineberger Comprehensive Cancer Center and colleagues have found that measuring activation of immune-system B cells may be better than measuring either T-cell activation or the total number of immune cells in and around a tumor, called tumor-infiltrating lymphocytes (TILs), in predicting whether HER2-positive breast cancer responds to treatment.

5 Jan 2023

T-DXd leads to longer overall survival in HER2-positive metastatic breast cancer patients than T-DM1

Second-line treatment with trastuzumab deruxtecan (T-DXd) led to significantly longer overall survival compared with trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer, according to updated results from the DESTINY-Breast03 phase III clinical trial presented at the San Antonio Breast Cancer Symposium, held December 6-10, 2022.

7 Dec 2022

T-DXd shows high efficacy in HER2-positive breast cancer patients previously treated with T-DM1

Compared with capecitabine-based regimens, trastuzumab deruxtecan (T-DXd) led to higher response rates and longer survival in the third-line setting for patients with HER2-positive metastatic breast cancer previously treated with trastuzumab emtansine (T-DM1), according to results from the phase III DESTINY-Breast02 trial presented at the San Antonio Breast Cancer Symposium, held December 6-10, 2022.

7 Dec 2022

Study reports overall response of HER2-low breast cancer patients to neoadjuvant T-DXd treatment

Patients with localized, hormone receptor-positive, HER2-low breast cancer treated with trastuzumab deruxtecan (T-DXd, Enhertu) in the neoadjuvant setting had an overall response rate of 75 percent in the absence of anastrozole and 63 percent in combination with anastrozole, according to results from the phase II TRIO-US B-12 TALENT trial presented at the San Antonio Breast Cancer Symposium, held December 6-10, 2022.

7 Dec 2022

Study determines how fibroblasts play a role in tumor's ability to generate anti-HER2 therapy resistance

A study led by researchers at the Hospital del Mar Medical Research Institute (IMIM-Hospital del Mar) has determined the role that fibroblasts, the cells that contribute to tissue formation, play in a tumor's ability to generate resistance to the most common biological treatment for HER2.

14 Oct 2022

Trastuzumab deruxtecan treatment maintains quality of life in HER2-low metastatic breast cancer patients

Patients who received trastuzumab deruxtecan (T-DXd) for human epidermal growth factor receptor 2 (HER2)-low metastatic breast cancer reported that the treatment maintained their quality of life (QoL) compared to conventional chemotherapy, according to results presented today by researchers from The University of Texas MD Anderson Cancer Center at the European Society for Medical Oncology Congress 2022.

13 Sep 2022

Alternative approaches to functional and phenotypic assays using multi-parameter flow cytometry

Synexa is an industry-leading biomarker and large molecule bio analytic research service provider. In this interview, NewsMedical speaks with Natalie Strickland, a principal scientist at Synexa, about alternative approaches to flow cytometry.

From Synexa Life Sciences BV 5 Sep 2022

Novel class of drug regresses active brain metastases in breast cancer patients

An Austrian study led by MedUni Vienna showed that active brain metastases in breast cancer patients are partially or even completely regressed by a novel class of drug. This is a chemical conjugate of an antibody and a chemotherapy drug that, according to current findings, opens up a completely new avenue in oncological research and targeted therapy.

10 Aug 2022

Biodegradable, non-ionic polymeric nanovesicles efficiently encapsulate and deliver siRNA

Small interfering RNAs, or siRNAs, hold promise to treat tumors, through their ability to specifically knock down oncogenes that promote tumor growth, without the toxicity that accompanies chemotherapy. However, the siRNAs need a delivery vehicle to protect them from degradation and clearance on their journey through the bloodstream to the cancer tumor.

25 May 2022

'Crown-like structures' surrounding breast tumors could hinder treatment response, study finds

A new study from the University of Southampton has discovered that 'crown-like structures' surrounding breast tumors in overweight and obese patients could hinder their response to therapy.

24 May 2022

Two Rutgers engineers create analytical tool to accelerate the production of biologic drugs

Two Rutgers engineers specializing in the process of making drugs derived from living organisms have created an analytical tool they expect will accelerate the discovery and production of biologic drugs that are often at the cutting edge of biomedical research.

18 May 2022

Drugs targeting DNA damage response pathway show therapeutic potential against advanced solid tumors

Results from early-stage clinical trials show two drugs that target the DNA damage response (DDR) pathway in cancers -; ATR inhibitor elimusertib and PARP inhibitor AZD5305 -; are safe and clinically beneficial in treating patients with advanced solid tumors.

11 Apr 2022

Better diagnostic tests needed to guide HER2 breast cancer treatment, study suggests

A new study by researchers at Yale Cancer Center shows using current standard human epidermal growth factor receptor 2 (HER2) assays as a diagnostic test may result in a mis-assignment of patients for treatment for breast cancer with a promising new drug.

3 Feb 2022

Peptide-enhanced antibody therapy may help treat breast cancer metastasis to bone

A moderate amount of a peptide-enhanced, biological cancer drug goes a long way in treating breast cancers that metastasize to the bone.

24 Jan 2022

Trastuzumab combined with trimodality treatment for HER2-overexpressing esophageal cancer found to be ineffective

The NRG Oncology clinical trial NRG-RTOG 1010, studying the addition of the drug trastuzumab to chemoradiation and surgery, did not reach its primary goal of improving disease-free survival (DFS) rates for patients with HER2 overexpressing esophageal adenocarcinoma.

22 Jan 2022

MR-guided focused ultrasound can safely deliver antibody therapy to Her2-positive brain metastases

In a first-in-world clinical trial, researchers at Sunnybrook Health Sciences Centre in Toronto, Canada, have demonstrated that magnetic resonance (MR)-guided focused ultrasound can be used to safely deliver antibody therapy to breast cancer that has metastasized to the brain.

13 Oct 2021

New antibody conjugate delivers drugs to bone tumors and inhibits metastasis

Bone cancer is hard to treat and prone to metastasis. Research teams at Rice University and Baylor College of Medicine have a new strategy to attack it.

23 Jun 2021

Combination of anti-HER2 breast cancer therapy and checkpoint inhibitor provides no benefit

Adding an immune checkpoint inhibitor to anti-HER2 treatment in breast cancer does not improve pathological complete response (pCR), according to the primary analysis of the IMpassion050 trial presented today during the ESMO Virtual Plenary.

18 Jun 2021

New radiopharmaceutical shows therapeutic efficacy in preclinical model of ovarian cancer

Preclinical trials of a new radiopharmaceutical to treat ovarian cancer have produced successful results, dramatically limiting tumor growth and decreasing tumor mass.

11 Jun 2021

New technology tricks tumors to eliminate itself through the production of anti-cancer agents

Scientists at the University of Zurich have modified a common respiratory virus, called adenovirus, to act like a Trojan horse to deliver genes for cancer therapeutics directly into tumor cells. Unlike chemotherapy or radiotherapy, this approach does no harm to normal healthy cells.

18 May 2021

Trastuzumab News and Research

Immune system B-cells may be better in predicting HER2-positive breast cancer treatment response

T-DXd leads to longer overall survival in HER2-positive metastatic breast cancer patients than T-DM1

T-DXd shows high efficacy in HER2-positive breast cancer patients previously treated with T-DM1

Study reports overall response of HER2-low breast cancer patients to neoadjuvant T-DXd treatment

Study determines how fibroblasts play a role in tumor's ability to generate anti-HER2 therapy resistance

Trastuzumab deruxtecan treatment maintains quality of life in HER2-low metastatic breast cancer patients

Alternative approaches to functional and phenotypic assays using multi-parameter flow cytometry

Novel class of drug regresses active brain metastases in breast cancer patients

Biodegradable, non-ionic polymeric nanovesicles efficiently encapsulate and deliver siRNA

'Crown-like structures' surrounding breast tumors could hinder treatment response, study finds

Two Rutgers engineers create analytical tool to accelerate the production of biologic drugs

Drugs targeting DNA damage response pathway show therapeutic potential against advanced solid tumors

Better diagnostic tests needed to guide HER2 breast cancer treatment, study suggests

Peptide-enhanced antibody therapy may help treat breast cancer metastasis to bone

Trastuzumab combined with trimodality treatment for HER2-overexpressing esophageal cancer found to be ineffective

MR-guided focused ultrasound can safely deliver antibody therapy to Her2-positive brain metastases

New antibody conjugate delivers drugs to bone tumors and inhibits metastasis

Combination of anti-HER2 breast cancer therapy and checkpoint inhibitor provides no benefit

New radiopharmaceutical shows therapeutic efficacy in preclinical model of ovarian cancer

New technology tricks tumors to eliminate itself through the production of anti-cancer agents

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News